Last reviewed · How we verify
IntragamP
IntragamP is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to modulate immune responses.
IntragamP is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to modulate immune responses. Used for Primary immunodeficiency disorders, Autoimmune and inflammatory conditions.
At a glance
| Generic name | IntragamP |
|---|---|
| Sponsor | CSL Limited |
| Drug class | Intravenous immunoglobulin (IVIG) |
| Target | Fc receptors, complement system, pathogenic antibodies |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As an IVIG product, IntragamP contains polyvalent immunoglobulins (primarily IgG) derived from pooled human plasma. It works through multiple mechanisms including neutralization of pathogenic antibodies, blockade of Fc receptors on immune cells, and modulation of complement activation and cytokine production. This results in immunomodulatory and anti-inflammatory effects useful in treating primary immunodeficiencies and autoimmune conditions.
Approved indications
- Primary immunodeficiency disorders
- Autoimmune and inflammatory conditions
Common side effects
- Headache
- Fever
- Chills
- Infusion reactions
- Thrombosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IntragamP CI brief — competitive landscape report
- IntragamP updates RSS · CI watch RSS
- CSL Limited portfolio CI